^{2nd Middle East Pharmacy and Pharmaceutical Conference}

Few data are available to evaluate health-related quality of life of people with irritable bowel syndrome(IBS) and fewer data are available for anxiety and depression status in this patients. patients with IBS included the study. All patients has given 40 mg otilonium bromide-80 mg simeticone combination drug (Simflat®(Abdi Ä°brahim Pharmaceuticals, Ä°stanbul/Turkey)) in one tablet 3 times a day on meal time. Qol questionnaire(QoL), beck anxiety index (BAI), Hamilton depression index (HDI) and Fibromiyalgia symptom severity index(FMSS) applied before the treatment and after the treatment on follow-up at 3rd month. After the treatment BAI and HDI showed statistically significant improvement (p< 0.05) for all groups. BAI 6.98/3.11 and HDI 9.28/1.36 before and after treatment. Qol improved 48.87 to 77.77 (p< 0.05) and FMSS decreased 4.11 from 7.98 after treatment (p< 0.05). 64 patients of 114 showed complete recovery for both ibs and fibromyalgia after treatment (%56.14). In

the symptomatic treatment of Irritable Bowel Disease co-excistent with fibromyalgia, a major treatment alternative since being scientifically proven for their effectiveness for many years, Otilonium Bromide and Simethicone. On the other hand, when evaluated in respect to biotechnologic window ,this combination product with its unique approach as distinct from other drugs, has brought patient compliance into the forefront in chronic gas and dyspepsy affiliated with IBS which has problematic diagnose and treatment issues. This is why, it has been brought two different molecules which are used widespread but separately into a single tablet formulation: Otilonium Bromide with its spasmolytic, pain transmission reducing and antisecretory effects and Simethicone with its reducing effects on pain caused by excessive gas. Otilonium Bromide, which is in solid form and Simethicone which is in liquid form, are combined with the bilayer tablet technology by and presented to physicians in a single tablet as an innovative product. In the symptomatic treatment of Irritable Bowel Disease, a major treatment alternative since being scientifically proven for their effectiveness for many years, Otilonium Bromide and Simethicone's single tablet feature improves patient compliance of IBS patients and leads to improve the quality of life of IBS patients.